Fortress Biotech/$FBIO
1D1W1MYTD1Y5YMAX
About Fortress Biotech
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
- Ticker
- $FBIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 78
- Headquarters
- Bay Harbor Islands, United States
- Website
- www.fortressbiotech.com
Fortress Biotech Metrics
BasicAdvanced
$92M
0.85
$3.25
1.21
-
Price and volume
Market cap
$92M
Beta
1.21
52-week high
$4.53
52-week low
$2.18
Average daily volume
643K
Financial strength
Current ratio
3.959
Quick ratio
3.762
Long term debt to equity
22.355
Total debt to equity
25.871
Interest coverage (TTM)
-3.07%
Profitability
EBITDA (TTM)
-24.979
Gross margin (TTM)
63.28%
Net profit margin (TTM)
163.32%
Operating margin (TTM)
-43.20%
Effective tax rate (TTM)
3.31%
Revenue per employee (TTM)
$880,000
Management effectiveness
Return on assets (TTM)
-7.76%
Return on equity (TTM)
115.99%
Valuation
Price to earnings (TTM)
0.852
Price to revenue (TTM)
1.23
Price to book
0.56
Price to tangible book (TTM)
0.67
Price to free cash flow (TTM)
0.669
Free cash flow yield (TTM)
149.46%
Free cash flow per share (TTM)
4.14
Growth
Revenue change (TTM)
15.46%
Earnings per share change (TTM)
-440.67%
3-year revenue growth (CAGR)
2.95%
10-year revenue growth (CAGR)
35.62%
3-year earnings per share growth (CAGR)
-41.09%
10-year earnings per share growth (CAGR)
-16.94%
What the Analysts think about Fortress Biotech
Analyst ratings (Buy, Hold, Sell) for Fortress Biotech stock.
Fortress Biotech Financial Performance
Revenues and expenses
Fortress Biotech Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.